Pacira BioSciences 

€13.4
16
+€0+0% 今天

統計

當日最高
13.4
當日最低
13.1
52週最高
-
52週最低
-
成交量
0
平均成交量
-
市值
550.52M
市盈率
9.83
股息收益率
-
股息
-

即將到來

收益

31Oct預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
0.53
0.65
0.77
0.89
預期每股收益
0.724889
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 82P.F 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Show more...
首席執行官
Mr. Charles A. Reinhart III, CPA, M.B.A.
員工
711
國家
US
ISIN
US6951271005
WKN
000A1H68T

上市公司